
EGFR Inhibitor Market Poised for 7.9% Growth Through 2036
The global market for EGFR inhibitors is projected to expand at a compound annual growth rate of 7.9% over the next decade, as a wave of next-generation tyrosine kinase inhibitors, antibody-drug conjugates, and combination immunotherapies prepare to enter the clinical landscape for lung, colorectal, and head and neck cancers.


























